For the second quarter of 2026, analysts anticipate Kailera Therapeutics will report a consensus net loss of $0.74 per share on zero revenue, with the stock currently trading at $17.17 against a bullish average price target of $42.75.
The primary focus for investors is the clinical execution of the ribupatide (KAI-9531) Phase 3 program and the optimization of titration schedules for its oral GLP-1 candidate, KAI-7535.
Recent stock volatility stems from concerns over high nausea rates observed in Chinese clinical trials, making management's updates on global trial designs and safety profiles critical for maintaining its premium valuation. Despite these concerns, the company’s massive $718 million April IPO provides a robust cash runway that is projected to fund clinical milestones through mid-2028.